Centessa Pharmaceuticals (CNTA) PT Raised to $5 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Nasdaq futures gain as SK Hynix lifts chips ahead of Fed decision, earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up over 1% as Saudi Arabian refinery attack reignites supply risk concerns
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
Tweet
Share
E-mailGet Alerts CNTA Hot Sheet
Price: $40.50 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 16
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 16
Join SI Premium – FREE
Goldman Sachs analyst Andrea Tan raised the price target on Centessa Pharmaceuticals (NASDAQ: CNTA) to $5.00 (from $4.50) while maintaining a Neutral rating.
You May Also Be Interested In
- Marzetti Company (MZTI) PT Lowered to $135 at Stephens
- TransUnion (TRU) PT Raised to $95 at Needham
- Visa (V) PT Raised to $455 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
